Brian Dorsey - Dec 11, 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Chief Operating Officer
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Dec 11, 2024
Transactions value $
-$468,259
Form type
4
Date filed
12/13/2024, 07:52 PM
Previous filing
Aug 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $9.6K +15K +249% $0.64 21K Dec 11, 2024 Direct
transaction SPRY Common Stock Sale -$186K -15K -71.35% $12.43 6.02K Dec 11, 2024 Direct F1, F2
transaction SPRY Common Stock Options Exercise $16K +25K +415.01% $0.64 31K Dec 12, 2024 Direct
transaction SPRY Common Stock Sale -$307K -25K -80.58% $12.30 6.02K Dec 12, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -15K -24.26% $0.00 46.8K Dec 11, 2024 Common Stock 15K $0.64 Direct F4
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -25K -53.39% $0.00 21.8K Dec 12, 2024 Common Stock 25K $0.64 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2023.
F2 The weighted average sale price for the transaction report was $12.4284, and the range of prices were between $12.34 and $12.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The weighted average sale price for the transaction report was $12.2973, and the range of prices were between $12.13 and $12.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 Immediately exercisable.